It reportedly inhibits cell growth in non-hormone-dependent cancer cells, such as MDA-MB-321 (breast cancer) (28) and LNCaP (prostate cancer) (29), which are negative for progesterone, estrogen and androgen receptors. This evidence concerns the gene AR and prostate carcinoma.